Jazz Pharmaceuticals, Oxford, England, OX4 2RW, UK.
Jazz Pharmaceuticals, Palo Alto, CA 94304, USA.
J Comp Eff Res. 2023 May;12(5):e220098. doi: 10.57264/cer-2022-0098. Epub 2023 Apr 20.
Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral and intravenous [IV] topotecan, and platinum re-challenge) identified by systematic literature review. Network meta-analysis methods estimated relative treatment effects. In platinum-sensitive patients, lurbinectedin demonstrated a survival benefit and favorable safety profile versus oral and IV topotecan and platinum re-challenge (overall survival, hazard ratio [HR]: 0.43; 95% credible interval [CrI]: 0.27, 0.67; HR: 0.43; 95% CrI: 0.26, 0.70; HR: 0.42; 95% CrI: 0.30, 0.58 respectively). Lurbinectedin showed a robust survival benefit and favorable safety versus other SCLC treatments in 2L platinum-sensitive SCLC.
比较洛布奈丁与其他二线（2L）小细胞肺癌（SCLC）治疗方案。一项单臂洛布奈丁试验的铂敏感 SCLC 队列通过系统文献回顾确定的网络，与三个随机对照试验（口服和静脉[IV]拓扑替康和铂再挑战）进行了无锚定匹配调整间接比较。网络荟萃分析方法估计了相对治疗效果。在铂敏感患者中，与口服和 IV 拓扑替康以及铂再挑战相比，洛布奈丁显示出生存获益和良好的安全性（总生存期，风险比[HR]：0.43；95%可信区间[CrI]：0.27，0.67；HR：0.43；95% CrI：0.26，0.70；HR：0.42；95% CrI：0.30，0.58）。在 2L 铂敏感 SCLC 中，洛布奈丁与其他 SCLC 治疗方案相比，具有强大的生存获益和良好的安全性。
